vimarsana.com
Home
Live Updates
Considerations When Deciding Between an IO/TKI and IO/IO Tre
Considerations When Deciding Between an IO/TKI and IO/IO Tre
Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
Related Keywords
,
New Wave ,
Renal Cell Carcinoma ,
Deciding Between ,
Patient With ,
Nrcc ,
Renal Cell Carcinoma Treatment ,
Asco Gu 2023 ,
Asco Gu Rcc ,
Rcc Treatment ,
Clear Cell Rcc ,
Non Clear Cell Rcc ,
Imdc Risk ,
Intermediate Risk ,
Tumor Shrinkage ,
Dose Reduction ,
Mskcc Prognostic Model ,